Observational Study
Copyright ©The Author(s) 2017.
World J Cardiol. Feb 26, 2017; 9(2): 167-173
Published online Feb 26, 2017. doi: 10.4330/wjc.v9.i2.167
Table 1 Baseline characteristics
AllEffective SMTIneffective SMTP-value
Number, n (%)618596 (96.3)22 (3.7)
Sex
Male, n47045218
Female, n1481444
Age (years)
Mean (± SD)66.4 (± 11)66.7 (± 10.6)54.6 (± 16.5)P = 0.0003
Median (IQR)69 (60-74)69 (62-74)54 (41-69)
LVEF (%)
Mean (± SD)31 (± 12.4)31 (± 12.5)26.9 (± 9.0)P = n.s.
Median (IQR)30 (22-35)30 (23-35)30 (20-35)
LVEF > 30%, n (%)248 (40.1)240 (36.9)8 (3.2)
LVEF < 30%, n (%)370 (59.9)356 (56.1)14 (3.8)P = n.s. (> 30% vs < 30%)
LVEF > 20%, n (%)334 (54.0)320 (49.8)14 (4.2)
LVEF < 20%, n (%)284 (46)276 (43.2)8 (2.8)P = n.s. (> 20% vs < 20%)
BMI (kg/m2)
Mean (± SD)28.4 (± 4.7)28 (± 4.7)29 (± 4.0)P = n.s.
Median (IQR)28 (17-28)28 (25-31)29 (25.5-33)
Indikation
Primary prevention, n (%)468 (76)452 (72.6)16 (3.4)
Secundary prevention, n (%)150 (24)144 (20)6 (4.0)P = n.s. (pp vs sp)
Type of arrhythmia for secondary prevention, n (%)
Sustained VT108 (72)106 (70.1)2 (1.9)
VF42 (28)38 (18.1)4 (9.5)P = 0.05 (VT vs VF)
SMT-Energy (J)
Mean (± SD)21 (± 2.3)20.8 (± 2.3)30.9 (± 2.0)
Median (IQR)20 (20-22)20 (20-20)30 (30-30)
Diagnosis
Non CAD, n (%)270254 (94.1)16 (5.9)
DCM (myocarditis), n (%)232 (85)218 (79)14 (6.0)
Other CM (non myocarditis), n (%)38 (15)36 (9.8)2 (5.2)
CAD, n (%)348342 (98.3)6 (1.7)P = 0.007 (nonCAD vs CAD)
Complete revascularized, n (%)196 (56)192 (54)4 (2.0)
Not complete revascularized, n (%)152 (44)150 (42.7)2 (1.3)P = n.s. (complete vs in-complete revascularized)
One vessel disease124 (81.6)122 (80.0)2 (1.6)
> One vessel disease28 (18.4)28 (18.4)0 (0)P = n.s. (one vesel vs > one)
Stenosed100 (65.8)100 (65.8)0 (0)
Occluded52 (34.2)50 (30.4)2 (3.8)P = n.s. (stenosed vs occluded)
Medication
Amiodaron medication, n (%)124 (20)118 (15.2)6 (4.8)
No amiodaron, n (%)494 (80)478 (76.8)16 (3.2)P = n.s. (amio vs no amio)